Allergic bronchopulmonary aspergillosis
What it is
Allergic bronchopulmonary aspergillosis, shortened to ABPA, affects 1% to 12% of immunocompetent patients with asthma. It is a disease of asthma, not of COPD, and that distinction matters when a nonsmoker with obstruction is being worked through.
Causes and risk
Asthma or cystic fibrosis is the ground it grows on. It is important to consider in patients with recurrent exacerbations.
How it presents
Recurrent wheezing and coughing over weeks, with the new production of brown sputum plugs, is the picture. In a described example, a woman with a long history of asthma and multiple allergies, treated four times in 3 months for asthma exacerbations, feels better on the first day of a corticosteroid, but any attempt at tapering leads to a recurrence of symptoms, despite previously good control on a regular high-dose inhaled corticosteroid and a long-acting agonist, and she returns with the same symptoms even after completing a course of levofloxacin for a suspected pneumonia. The examination is unremarkable apart from diffuse expiratory wheezing, with no fever and no other abnormal vital signs.
How it is diagnosed
The symptoms alone are insufficient for a diagnosis, but they should prompt consideration of it, since some of them are themselves part of the criteria. The major diagnostic criteria include:
- Asthma or cystic fibrosis.
- Immediate skin reactivity to Aspergillus antigens.
- Peripheral eosinophilia.
- Transient pulmonary infiltrates or opacities.
- Central bronchiectasis on a chest radiograph or CT.
- Serum precipitating antibodies to Aspergillus fumigatus.
- Elevated Aspergillus IgE- and/or IgG-specific antibodies.
Minor criteria that support the diagnosis include the production of brownish mucus plugs, identification of Aspergillus in the sputum, and delayed skin sensitivity to Aspergillus.
On the film, opacities in the upper and middle lobes with eosinophilia on the CBC fit. What it is separated from: pneumonia is unlikely without fever, chills, tachycardia, tachypnea, pleuritic chest pain and a cough productive of mucopurulent sputum, and after recent treatment with a respiratory fluoroquinolone; pulmonary embolism most commonly gives dyspnea, chest pain, syncope, tachypnea and cough; and medication nonadherence, though it may increase asthma exacerbations and wheezing, would not explain new brown mucus production.